CymaBay Therapeutics - CBAY Stock Forecast, Price & News

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Wall Street Analyst Weigh In

Several research analysts have recently commented on CBAY shares. B. Riley decreased their price objective on CymaBay Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, May 18th. HC Wainwright cut their target price on CymaBay Therapeutics from $12.00 to $10.00 and set a "na" rating on the stock in a research note on Monday, May 16th. Oppenheimer cut their target price on CymaBay Therapeutics to $12.00 and set a "na" rating on the stock in a research note on Monday, May 16th. Finally, StockNews.com raised CymaBay Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday. One research analyst has rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, CymaBay Therapeutics currently has an average rating of "Buy" and a consensus target price of $11.00.

CymaBay Therapeutics Stock Performance

Shares of CBAY Stock traded down $0.14 during trading hours on Tuesday, hitting $3.91. 446,801 shares of the company's stock traded hands, compared to its average volume of 611,114. The stock's fifty day simple moving average is $3.05 and its two-hundred day simple moving average is $2.87. CymaBay Therapeutics has a 12-month low of $1.67 and a 12-month high of $4.74. The company has a debt-to-equity ratio of 1.00, a current ratio of 13.27 and a quick ratio of 13.27.

CymaBay Therapeutics (NASDAQ:CBAY - Get Rating) last announced its quarterly earnings data on Thursday, August 11th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.01). During the same period in the prior year, the firm posted ($0.34) EPS. As a group, sell-side analysts predict that CymaBay Therapeutics will post -1.23 EPS for the current year.

Insider Buying and Selling

In related news, CEO Sujal Shah bought 51,301 shares of the firm's stock in a transaction on Monday, June 6th. The stock was acquired at an average cost of $1.95 per share, for a total transaction of $100,036.95. Following the purchase, the chief executive officer now owns 171,301 shares in the company, valued at $334,036.95. The acquisition was disclosed in a filing with the SEC, which is available through this link. 5.50% of the stock is owned by company insiders.